Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 12:00 ET | Source: Kailera Therapeutics, Inc.; Hengrui Pharma

Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

Hengrui Pharma & Kailera Therapeutics Present Additional Data from Phase 3 Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 at Obesity Week
October 21, 2025 07:00 ET | Source: Kailera Therapeutics, Inc.

Hengrui Pharma and Kailera Therapeutics Announce Phase 3 HRS9531 Obesity Data Presentation at ObesityWeek® 2025

Hengrui Pharma and Kailera today announced an oral presentation of HRS9531 Phase 3 data at ObesityWeek® 2025, the annual meeting of the Obesity Society.
October 01, 2024 07:00 ET | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions

Kailera today announced its launch as a clinical-stage biopharmaceutical company advancing next-generation therapies for obesity and related conditions.